ATE266000T1 - Hydroxamsäure- und carbonsäure-derivate mit mmp und tnf hemmender wirkung - Google Patents

Hydroxamsäure- und carbonsäure-derivate mit mmp und tnf hemmender wirkung

Info

Publication number
ATE266000T1
ATE266000T1 AT97935666T AT97935666T ATE266000T1 AT E266000 T1 ATE266000 T1 AT E266000T1 AT 97935666 T AT97935666 T AT 97935666T AT 97935666 T AT97935666 T AT 97935666T AT E266000 T1 ATE266000 T1 AT E266000T1
Authority
AT
Austria
Prior art keywords
mmp
carboxic
inhibiting effects
acid
acid derivatives
Prior art date
Application number
AT97935666T
Other languages
German (de)
English (en)
Inventor
David Alan Owen
John Gary Montana
John Fraser Keily
Robert John Watson
Andrew Douglas Baxter
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9616599.8A external-priority patent/GB9616599D0/en
Priority claimed from GBGB9707427.2A external-priority patent/GB9707427D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Application granted granted Critical
Publication of ATE266000T1 publication Critical patent/ATE266000T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Indole Compounds (AREA)
AT97935666T 1996-08-07 1997-08-07 Hydroxamsäure- und carbonsäure-derivate mit mmp und tnf hemmender wirkung ATE266000T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9616599.8A GB9616599D0 (en) 1996-08-07 1996-08-07 Compounds
GBGB9707427.2A GB9707427D0 (en) 1997-04-11 1997-04-11 Compounds having mmp and tnf inhibitory activity
PCT/GB1997/002129 WO1998005635A1 (en) 1996-08-07 1997-08-07 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity

Publications (1)

Publication Number Publication Date
ATE266000T1 true ATE266000T1 (de) 2004-05-15

Family

ID=26309836

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97935666T ATE266000T1 (de) 1996-08-07 1997-08-07 Hydroxamsäure- und carbonsäure-derivate mit mmp und tnf hemmender wirkung

Country Status (17)

Country Link
US (1) US6118001A (https=)
EP (1) EP0968182B1 (https=)
JP (1) JP2000517297A (https=)
KR (1) KR20000029858A (https=)
CN (1) CN1227540A (https=)
AT (1) ATE266000T1 (https=)
AU (1) AU730464B2 (https=)
BR (1) BR9711027A (https=)
CA (1) CA2263154A1 (https=)
CZ (1) CZ297278B6 (https=)
DE (1) DE69729007T2 (https=)
DK (1) DK0968182T3 (https=)
ES (1) ES2217425T3 (https=)
NO (1) NO314452B1 (https=)
PL (1) PL193829B1 (https=)
PT (1) PT968182E (https=)
WO (1) WO1998005635A1 (https=)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE292622T1 (de) * 1997-01-22 2005-04-15 Aventis Pharma Inc Substituierte beta-thiocarbonsäuren
US6696449B2 (en) 1997-03-04 2004-02-24 Pharmacia Corporation Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
NZ337326A (en) * 1997-03-04 2001-05-25 Monsanto Co Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds to inhibit the activity of matrix metalloproteinases
US6476027B1 (en) 1997-03-04 2002-11-05 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
US6794511B2 (en) * 1997-03-04 2004-09-21 G. D. Searle Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US7115632B1 (en) 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
AUPO721997A0 (en) * 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
KR20010032319A (ko) 1997-11-21 2001-04-16 로렌스 티. 마이젠헬더 매트릭스 메탈로프로테이나제 억제제로서 β-술포닐히드록스아민산의 α-히드록시, -아미노 및 -플루오로유도체
EP0965592A1 (en) 1998-06-18 1999-12-22 F. Hoffmann-La Roche Ag Process for preparing 3-arylsulfur hydroxamic acids
FR2780402B1 (fr) * 1998-06-30 2001-04-27 Adir Nouveaux composes acides carboxyliques et hydroxamiques inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6479502B1 (en) 1998-08-29 2002-11-12 British Biotech Pharmaceuticals Hydroxamic acid derivatives as proteinase inhibitors
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
GB9911075D0 (en) 1999-05-12 1999-07-14 Darwin Discovery Ltd HYdroxamic and carboxylic acid derivatives
GB9911073D0 (en) * 1999-05-12 1999-07-14 Darwin Discovery Ltd Hydroxamic and carboxylic acid derivatives
GB9916562D0 (en) * 1999-07-14 1999-09-15 Pharmacia & Upjohn Spa 3-Arylsulfonyl-2-(substituted-methyl) propanoic acid derivatives as matrix metalloproteinase inhibitora
GB9922825D0 (en) * 1999-09-25 1999-11-24 Smithkline Beecham Biolog Medical use
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
KR20020079882A (ko) * 2000-02-21 2002-10-19 아스트라제네카 아베 아릴피페라진 및 아릴피페리딘 및 금속단백질분해효소억제제로서의 그의 용도
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
EP1282614B1 (en) 2000-05-15 2003-11-12 Darwin Discovery Limited Hydroxamic acid derivatives
JP2003533513A (ja) 2000-05-15 2003-11-11 ダーウィン・ディスカバリー・リミテッド Ｍｍｐおよびｔｎｆ阻害活性を有するヒドロキサム酸およびカルボン酸誘導体
EP1286994A1 (en) * 2000-05-15 2003-03-05 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
GB0020498D0 (en) 2000-08-18 2000-10-11 Sterix Ltd Compound
US7842727B2 (en) 2001-03-27 2010-11-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7214831B2 (en) * 2002-05-22 2007-05-08 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on alpha-chalcogenmethylcarbonyl compounds
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
GB0119474D0 (en) 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
EP1511477A4 (en) 2002-05-22 2008-04-09 Errant Gene Therapeutics Llc HISTONE DEACETYLASE INHIBITORS BASED ON ALPHA-KETO-EPOXYDE COMPOUNDS
DE10226370B4 (de) 2002-06-13 2008-12-11 Polyic Gmbh & Co. Kg Substrat für ein elektronisches Bauteil, Verwendung des Substrates, Verfahren zur Erhöhung der Ladungsträgermobilität und Organischer Feld-Effekt Transistor (OFET)
DE10233085B4 (de) 2002-07-19 2014-02-20 Dendron Gmbh Stent mit Führungsdraht
US8425549B2 (en) 2002-07-23 2013-04-23 Reverse Medical Corporation Systems and methods for removing obstructive matter from body lumens and treating vascular defects
US7102008B2 (en) 2002-08-01 2006-09-05 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
GB0411562D0 (en) 2004-05-24 2004-06-23 Sterix Ltd Compound
GB0412492D0 (en) 2004-06-04 2004-07-07 Sterix Ltd Compound
US20050277897A1 (en) * 2004-06-14 2005-12-15 Ghannoum Ziad R Handpiece tip
BRPI0610842A2 (pt) * 2005-04-25 2010-07-27 Novartis Ag derivados de imidazo(1,2-a) piridina úteis como inibidores de peptìdeo desformilase (pdf)
DE102005019181A1 (de) * 2005-04-25 2006-10-26 Novartis Ag Peptid-Deformylase (PDF) Inhibitoren 1
CA2609142C (en) 2005-05-27 2016-02-09 Fondazione Centro San Raffaele Del Monte Tabor Therapeutic gene vectors comprising mirna target sequences
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
GB0526210D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Vectors
GB0604142D0 (en) 2006-03-01 2006-04-12 Sterix Ltd Compound
DK2041181T3 (da) * 2006-06-08 2011-08-29 Helmholtz Zentrum Muenchen Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi
ES2745411T3 (es) * 2006-07-27 2020-03-02 Wang Nai Fang Compuestos y composiciones de arilsulfanilo para administración de agentes activos
GB0706072D0 (en) 2007-03-28 2007-05-09 Sterix Ltd Compound
US8088140B2 (en) 2008-05-19 2012-01-03 Mindframe, Inc. Blood flow restorative and embolus removal methods
US11337714B2 (en) 2007-10-17 2022-05-24 Covidien Lp Restoring blood flow and clot removal during acute ischemic stroke
GB0722779D0 (en) 2007-11-20 2008-01-02 Sterix Ltd Compound
EP2254485B1 (en) 2008-02-22 2017-08-30 Covidien LP Apparatus for flow restoration
DK2307551T3 (en) 2008-06-18 2017-03-20 Oxford Biomedica (Uk) Ltd CLEANING RETROVIRAL VECTORS
EP2364362B1 (en) 2008-11-12 2015-10-21 Ospedale San Raffaele S.r.l. Gene vector for inducing transgene-specific immune tolerance
PL2424571T3 (pl) 2009-04-30 2020-10-19 Ospedale San Raffaele S.R.L Wektor genowy
GB0914767D0 (en) 2009-08-24 2009-09-30 Sterix Ltd Compound
US9039749B2 (en) 2010-10-01 2015-05-26 Covidien Lp Methods and apparatuses for flow restoration and implanting members in the human body
WO2012156839A2 (en) 2011-05-19 2012-11-22 Ospedale San Raffaele S.R.L. New generation of splice-less lentiviral vectors for safer gene therapy applications
ES2627281T3 (es) 2013-02-06 2017-07-27 Merck Patent Gmbh Derivados del ácido carboxílico sustituidos como agregados agrecanasa para el tratamiento de la artrosis
AU2014229506B2 (en) 2013-03-11 2017-04-13 Nobesita As Natural lipids containing non-oxidizable fatty acids
US10076399B2 (en) 2013-09-13 2018-09-18 Covidien Lp Endovascular device engagement
EP3060670B1 (en) 2013-10-24 2019-07-10 Ospedale San Raffaele S.r.l. Method
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
GB201407322D0 (en) 2014-04-25 2014-06-11 Ospedale San Raffaele Gene therapy
GB201412494D0 (en) 2014-07-14 2014-08-27 Ospedale San Raffaele And Fond Telethon Vector production
GB201418965D0 (https=) 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
GB201608944D0 (en) 2016-05-20 2016-07-06 Ospedale San Raffaele And Fond Telethon Gene Tharapy
GB201706394D0 (en) 2017-04-21 2017-06-07 Ospedale San Raffaele Srl Gene Therapy
DE102017211110A1 (de) * 2017-06-30 2019-01-03 Continental Reifen Deutschland Gmbh Verfahren zur Herstellung eines Silans, Verfahren zur Modifizierung einer Kieselsäure mit dem Silan und modifizierte Kieselsäure
GB201807945D0 (en) 2018-05-16 2018-06-27 Ospedale San Raffaele Srl Vector production
GB201807944D0 (en) 2018-05-16 2018-06-27 Ospedale San Raffaele Srl Compositions and methods for haematopoietic stem cell transplantation
AU2019294294A1 (en) 2018-06-25 2021-02-11 Fondazione Telethon Ets Gene therapy
WO2020074729A1 (en) 2018-10-11 2020-04-16 Ospedale San Raffaele S.R.L Selection by means of artificial transactivators
JP7677893B2 (ja) 2019-01-18 2025-05-15 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 幹細胞機能を向上させるための薬剤及び方法
WO2021094752A1 (en) 2019-11-12 2021-05-20 Oxford Biomedica (Uk) Limited Production system
EP4103723A1 (en) 2020-02-13 2022-12-21 Oxford BioMedica (UK) Limited Production of lentiviral vectors
WO2021181108A1 (en) 2020-03-13 2021-09-16 Oxford Biomedica (Uk) Limited Lentiviral vectors
GB202007106D0 (en) 2020-05-14 2020-07-01 Ucl Business Plc Cyclosporine analogues
GB202007199D0 (en) 2020-05-15 2020-07-01 Oxford Biomedica Ltd Viral vector production
CA3188667A1 (en) 2020-09-28 2022-03-31 Nicola Vannini Compositions and methods for increasing stem cell function
BR112023005370A2 (pt) 2020-09-28 2023-05-09 Nestle Sa Composições e métodos para aumentar função das células-tronco
GB202017725D0 (en) 2020-11-10 2020-12-23 Oxford Biomedica Ltd Method
CA3207166A1 (en) 2021-02-01 2022-08-04 Angelo Leone Lombardo Gene silencing
AU2021202658A1 (en) 2021-04-28 2022-11-17 Fondazione Telethon Gene therapy
AU2022270331A1 (en) 2021-05-05 2023-10-12 Ludwig Institute For Cancer Research Urolithin for increasing stem cell function
GB202114532D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral Vectors
GB202114530D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Retroviral vectors
GB202114534D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Novel viral regulatory elements
GB202114529D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114528D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114972D0 (en) 2021-10-19 2021-12-01 Ospedale San Raffaele Srl Gene therapy
GB202117844D0 (en) 2021-12-09 2022-01-26 Oxford Biomedica Ltd Purification method
US20250281540A1 (en) 2022-04-28 2025-09-11 Ospedale San Raffaele S.R.L. Methods for Haematopoietic Stem Cell Transplantation
GB202206346D0 (en) 2022-04-29 2022-06-15 Ospedale San Raffaele Srl Gene therapy
GB202209098D0 (en) 2022-06-21 2022-08-10 Ucl Business Ltd Cyclosporine analogues
GB202211935D0 (en) 2022-08-16 2022-09-28 Oxford Biomedica Ltd envelope proteins
EP4602153A1 (en) 2022-10-11 2025-08-20 Fondazione Telethon ETS 3d cell culture methods
IT202300011790A1 (it) 2023-06-08 2024-12-08 Fond Telethon Ets Protocolli di manipolazione genica in cellule immunitarie

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4098824A (en) * 1975-10-02 1978-07-04 Laboratoire L. Lafon Benzhydrylsulphinyl derivatives
DE2804576A1 (de) * 1977-02-15 1978-08-17 Lafon Labor Phenylamidin-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
AU3899193A (en) * 1992-04-07 1993-11-08 British Bio-Technology Limited Hydroxamic acid based collagenase and cytokine inhibitors
GB9404046D0 (en) * 1994-03-03 1994-04-20 Smithkline Beecham Corp Novel compounds
AU692102B2 (en) * 1995-05-10 1998-05-28 Darwin Discovery Limited Peptidyl compounds and their therapeutic use
US5665777A (en) * 1995-11-14 1997-09-09 Abbott Laboratories Biphenyl hydroxamate inhibitors of matrix metalloproteinases
ATE225343T1 (de) * 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
PT871439E (pt) * 1996-01-02 2004-08-31 Aventis Pharma Inc Compostos do acido hidroxamico substituidos (arilo heteroarilo arilmetilo ou heteroarilmetilo)
KR20000048639A (ko) * 1996-09-27 2000-07-25 로렌스 티. 마이젠헬더 매트릭스 메탈로프로테이나제 억제제인 베타-술포닐 히드록삼산
US6476027B1 (en) * 1997-03-04 2002-11-05 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds

Also Published As

Publication number Publication date
NO990543L (no) 1999-04-06
CN1227540A (zh) 1999-09-01
KR20000029858A (ko) 2000-05-25
AU3856497A (en) 1998-02-25
WO1998005635A1 (en) 1998-02-12
NO314452B1 (no) 2003-03-24
PT968182E (pt) 2004-08-31
DE69729007T2 (de) 2005-04-07
EP0968182A1 (en) 2000-01-05
CZ297278B6 (cs) 2006-10-11
DK0968182T3 (da) 2004-08-16
CZ36899A3 (cs) 1999-07-14
ES2217425T3 (es) 2004-11-01
CA2263154A1 (en) 1998-02-12
PL193829B1 (pl) 2007-03-30
AU730464B2 (en) 2001-03-08
US6118001A (en) 2000-09-12
BR9711027A (pt) 1999-08-17
JP2000517297A (ja) 2000-12-26
EP0968182B1 (en) 2004-05-06
DE69729007D1 (de) 2004-06-09
NO990543D0 (no) 1999-02-05
PL331598A1 (en) 1999-08-02

Similar Documents

Publication Publication Date Title
ATE266000T1 (de) Hydroxamsäure- und carbonsäure-derivate mit mmp und tnf hemmender wirkung
PT1109787E (pt) Arilpiperazinas e sua utilizacao como inibidores de metaloproteinases
FI973974L (fi) Aryylisulfonyylihydroksaamihappojohdannaisia MMP- ja TNF-inhibiittoreina
TR199802676A2 (xx) T�m�rlerin, t�m�rle ilgili hastal�klar�n ve ka�eksinin tedavisi ve �nlenmesi i�in y�ntem.
BR9908280A (pt) Inibidores de enzimas de fosfolipase
DE69939864D1 (de) Ppar-gamma modulatoren
UY27972A1 (es) Derivados de hidantoína
IS4955A (is) Tálmar gegn frumusamloðun
ATE219058T1 (de) Alpha-substituierte arylsulphonamidohydroxamsaüre als tnf-alpha und matrix-metalloproteinase- inhibitoren
FI973360A7 (fi) Uusia dipeptidisiä amidiineja trombiininestäjiksi
BR9811099A (pt) Inibidores de urocinase
FI942625A7 (fi) Peptidisiä fosfinyylioksimetyyliketoneja interleukiini-1beta-muuttuvan entsyymin inhibiittoreina
NO981520D0 (no) Tiosubstituerte peptider som inhibitorer for metalloproteinaser og TNF-frigjöring
DK0910573T3 (da) Nye aminosyrederivater og deres anvendelse som thrombininhibitorer
ATE226592T1 (de) Peptide, die metallproteinasen und die tnf- freisetzung hemmen, und ihre therapeutische verwendung
EE03745B1 (et) Asendatud 4-bifenüül-4-hüdroksübutaanhappe derivaadid metalloproteaasimaatriksi inhibiitoritena
ATE229034T1 (de) 3-mercaptoacetylamino-1,5-substituierte-2-oxo- azepan derivate und deren verwendung als inhibitoren von matrix-metalloproteinasen
ATE237630T1 (de) Peptidartige stoffe, die metalloproteinasen und die tnf-freisetzung hemmen, und ihre therapeutische verwendung
ES2186807T3 (es) Inhibidores de trombina.
BG100248A (bg) Инхибитори на скваленсинтетаза
MXPA02011558A (es) Inhibidores de mmp-2/mp-9 novedosos.
DE69828638D1 (de) Hydroxam- und carbonsäurederivate mit mmp- und tnf-hemmender aktivität
DE69821228T2 (de) Selektive mmp inhibitoren mit verringerten nebenwirkungen
ATE228372T1 (de) Hcg und derivate als matrixmetalloprotease- inhibitoren
BR0112460A (pt) Método para tratamento de sépsis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0968182

Country of ref document: EP

REN Ceased due to non-payment of the annual fee